Evidence map›Paper›PMID 38063270›Full record

ArticleOncology reports2024

Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS.

Tomoyuki Nanamiya, Kiyoko Takane, Kiyoshi Yamaguchi, Yuya Okawara, Mariko Arakawa, Akari Saku, Tsuneo Ikenoue, Tomoko Fujiyuki, Misako Yoneda, Chieko Kai and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Tomoyuki Nanamiya *Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.
Kiyoko Takane *Division of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.
Kiyoshi YamaguchiDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.
Yuya OkawaraDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.
Mariko ArakawaDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.
Akari SakuDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.
Tsuneo IkenoueDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.
Tomoko FujiyukiDivision of Virus Engineering, Institute of Industrial Science, The University of Tokyo, Tokyo 153‑8505, Japan.
Misako YonedaDivision of Virological Medicine, Institute of Industrial Science, The University of Tokyo, Tokyo 153‑8505, Japan.
Chieko KaiDivision of Infectious Disease Control Science, Institute of Industrial Science, The University of Tokyo, Tokyo 153‑8505, Japan.
Yoichi FurukawaDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan.
The University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PVRL4 (or nectin‑4) is a promising therapeutic target since its upregulated expression is found in a wide range of human cancer types. Enfortumab vedotin, an antibody‑drug conjugate targeting PVRL4, is clinically used for the treatment of urothelial bladder cancer. In addition, rMV‑SLAMblind, a genetically engineered oncolytic measles virus, can infect cancer cells and induce apoptosis through interaction with PVRL4. Although

Indexed as

Breast NeoplasmsNectinsOncolytic VirusesCell Adhesion MoleculesFemaleHumansMeasles virusProto-Oncogene Proteins c-fosRNA, Small InterferingCell Adhesion MoleculesNECTIN4 protein, humanNectinsProto-Oncogene Proteins c-fosRNA, Small Interferingbreast cancerFOSnectin‑4PVRL4

Identifiers

PMID38063270
PMCPMC10739986
OpenAlexW4389342155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.